Financial Performance - The company's revenue for the year ended December 31, 2022, was approximately RMB 1,097.3 million, an increase of about 18.6% compared to RMB 925.3 million in the same period of 2021[2] - Gross profit for the year ended December 31, 2022, was approximately RMB 873.9 million, up about 16.9% from RMB 747.5 million in 2021[2] - The net profit attributable to the owners of the company for the year ended December 31, 2022, was approximately RMB 429.3 million, representing a growth of about 32.5% from RMB 324.0 million in 2021[2] - The total comprehensive income for the year was RMB 510.1 million, compared to RMB 285.4 million in the previous year[5] - Basic earnings per share for the year was RMB 7.7 cents, compared to RMB 6.8 cents in 2021[5] - The total segment profit for the year ended December 31, 2022, was RMB 874,015,000, compared to RMB 755,801,000 in the previous year, indicating an increase of about 15.6%[15] - The company reported a pre-tax profit of RMB 378,046,000 for the year ended December 31, 2022, compared to RMB 332,928,000 in the previous year, marking an increase of approximately 13.5%[15] - The company achieved a net profit attributable to shareholders of approximately RMB 429.3 million for the year ended December 31, 2022, representing a growth of about 32.5% compared to RMB 324.0 million in 2021[57] Sales and Revenue Breakdown - The company's overseas sales increased by approximately 33.7% compared to the same period in 2021[2] - Revenue from external customers in mainland China reached RMB 895,053 thousand in 2022, compared to RMB 774,035 thousand in 2021, reflecting a growth of 15.6%[23] - Revenue from the structural heart disease business was approximately RMB 394.6 million, representing a growth of about 19.2% from RMB 331.1 million in the previous year, with congenital heart disease occluders and left atrial appendage occluders seeing revenue increases of approximately 26.2% and 8.4%, respectively[43] - Revenue from the peripheral vascular business was approximately RMB 644.3 million, an increase of about 17.5% from RMB 548.5 million in the previous year, with sales of coated stents increasing by approximately 23.3%[44] - Domestic sales accounted for approximately 81.6% of total revenue for the year ended December 31, 2022, down from 83.6% in 2021[37] - The company's revenue for the year ended December 31, 2022, was approximately RMB 1,097.3 million, primarily driven by increased sales of coated stents and congenital heart disease occluders[42] Assets and Liabilities - Non-current assets as of December 31, 2022, totaled RMB 2,293.4 million, an increase from RMB 1,346.6 million in 2021[6] - The total assets less current liabilities amounted to RMB 3,105.4 million, compared to RMB 2,701.8 million in the previous year[6] - The company reported a total asset of RMB 3,690,103 thousand in 2022, up from RMB 3,183,715 thousand in 2021, indicating an increase of 15.9%[18] - The total liabilities of the company increased to RMB 769,046 thousand in 2022 from RMB 653,613 thousand in 2021, which is a rise of 17.7%[19] - The company's total current assets as of December 31, 2022, were approximately RMB 1,396.7 million, down from RMB 1,837.1 million in 2021, while total current liabilities increased to RMB 584.7 million from RMB 481.9 million[58] Research and Development - Research and development expenses for the year were RMB 208,481,000, reflecting the company's commitment to innovation and product development[15] - Research and development expenses rose by 42.9% to approximately RMB 208.5 million, with capitalized development expenditures of approximately RMB 109.0 million, leading to a total R&D cost increase of about 49.4% to RMB 317.5 million[50] - The company is developing a fourth-generation congenital heart disease occluder to meet diverse patient needs, indicating a focus on innovative technology[69] - The company’s R&D efforts led to the successful completion of clinical trials for the IBS™ absorbable drug-eluting coronary stent system, achieving a 100% success rate without serious adverse events[40] Corporate Governance and Compliance - The company is reviewing and enhancing its corporate governance practices to comply with the new corporate governance code effective from January 1, 2022[77] - The company's financial statements for the year ended December 31, 2022, have been agreed upon by the auditor, Deloitte[84] - The audited annual performance for the year ended December 31, 2022, has been reviewed by the audit committee, confirming compliance with applicable accounting standards and sufficient disclosure[87] Employee and Operational Insights - The group employs 1,299 full-time employees as of December 31, 2022, up from 943 in 2021, with total employee costs amounting to approximately RMB 336.5 million[72] - The company is committed to maintaining good relationships with employees, customers, and suppliers to achieve its long-term goals[82] Strategic Initiatives - The company is focused on identifying growth opportunities in the healthcare sector and seeks strategic partnerships to enhance its product offerings and expand its business scale[62] - The company has established a strategic cooperation agreement with Jian Shi Technology for potential business development and project investment in both domestic and overseas markets[74] - The company aims to enhance its innovation capabilities and optimize its production and sales model to increase global market share and international influence[75] Capital Expenditure and Investments - The group's capital expenditure for the year ended December 31, 2022, was approximately RMB 332.0 million, an increase from RMB 301.3 million in 2021[64] - The company holds a strategic investment in Ningbo Jianshi Technology Co., Ltd., with a fair value of RMB 335.4 million as of December 31, 2022, accounting for about 9.1% of total assets[54] Market Presence - The company’s distribution network spans multiple countries across Asia, Africa, North America, South America, and Europe, enhancing its global market presence[36] - The market demand for left atrial appendage occluders is expected to continue expanding due to a large global population of atrial fibrillation patients[69]
先健科技(01302) - 2022 - 年度业绩